Namibia vs Pre-demographic dividend: Antiretroviral therapy coverage for PMTCT
Namibia
97.0%
in 2024
Pre-demographic dividend
84.4%
in 2024
Namibia rank
12th
Pre-demographic dividend rank
9th
Antiretroviral therapy coverage for PMTCT over time
- Namibia
- Pre-demographic dividend
How they compare
Namibia currently reports 97.0% against 84.4% in Pre-demographic dividend, a difference of 12.6%.
That makes Namibia's figure about 1.1 times Pre-demographic dividend's.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Pre-demographic dividend ahead.
Namibia ranks 12th and Pre-demographic dividend ranks 9th of 84 countries.
Namibia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Namibia | Pre-demographic dividend | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 29.5% | 18.1% | 11.4% | Namibia |
| 2010s | 82.0% | 69.9% | 12.1% | Namibia |
| 2020s | 97.0% | 84.0% | 13.0% | Namibia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Namibia or Pre-demographic dividend?
- Namibia, at 97.0% against 84.4% in Pre-demographic dividend as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Namibia and Pre-demographic dividend?
- 12.6%, with Namibia ahead.
- How many years of comparable data are there for Namibia and Pre-demographic dividend?
- 25 years are reported by both, from 2000 to 2024.
- How do Namibia and Pre-demographic dividend rank globally for antiretroviral therapy coverage for pmtct?
- Namibia ranks 12th and Pre-demographic dividend ranks 9th of 84 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).